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Abstract  
 
Objective: To identify and assess the methods for estimating comparative clinical 
effectiveness for novel pharmaceutical products licensed on the basis of non-RCT data and 
to evaluate the corresponding NICE recommendations.  
Methods: Our identification strategy was two-fold. First, we reviewed all NICE appraisals 
between 2010 and 2016 and identified technologies where comparative clinical effectiveness 
estimates were calculated using non-RCT data. Second, we checked if NICE appraisals 
completed from 2000 to 2010 had included pharmaceuticals that were granted EMA 
marketing authorisation without RCT data between 1999-2014. Information was extracted on 
the methods used as well as the corresponding NICE recommendations. We also collected 
information on the rationale for utilising non-RCT data in NICE appraisals.  
Results: Of 489 individual pharmaceutical technologies assessed by NICE, 22 (4%) used 
non-RCT data to estimate comparative clinical effectiveness. Methods for establishing 
external controls in such studies varied: 13 (59%) used published trials, 6 (27%) used 
observational data, 2 (9%) used expert opinion, and 1 (5%) used a responder vs non-
responder analysis. Only 5 (23%) used a regression model to adjust for covariates. We did 
not observe a notable difference in the proportion of pharmaceutical technologies that 
received a positive recommendation from NICE whether the decision was based on RCT or 
non-RCT data. (83% vs 86%) 
Conclusions: To date, the small number of appraisals by NICE based on non-RCT data did 
not result in substantially different treatment decisions. The majority of the technologies 
appraised on the basis of non-RCT data either received a positive recommendation or a 
positive recommendation with restrictions. The methods used to calculate comparative 
clinical effectiveness estimates varied, highlighting the need to establish clear guidance.  
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What is new? 
Key findings 
• Between 2000-2016, 22 of the 489 (4%) individual pharmaceutical technologies 
assessed by NICE were based upon comparative clinical effectiveness estimates 
calculated using non-RCT data. Out of these: 
• 11 (50%) were included in technology appraisals published in either 2015 or 2016. 
• 10 (45%) received a positive recommendation from NICE, 9 (41%) received an 
optimised recommendation and a further 3 (14%) received a negative 
recommendation 
• 14 (64%) appraisals calculated comparative clinical effectiveness estimates using a 
naive unadjusted indirect comparison against an external control, not utilising any 
regression methods. This may reflect the limited availability of individual patient 
level data to adjust for covariates.  
 
What this adds to what was known? 
• Despite non-RCT data leading to significant uncertainty in quantifying clinical 
benefit, we only observed a small differences in the proportion of pharmaceutical 
technologies that received a positive or negative recommendation from NICE when 
comparing decisions based on RCT or non-RCT data. 
 
What is the implication and what should change now? 
• Clear guidance is needed to establish the comparative clinical effectiveness of 
pharmaceuticals with non-RCT data.  
• There is a need to monitor and follow-up the real-world comparative clinical and 
cost effectiveness of pharmaceutical technologies recommended on the basis of 
non-RCT data. 
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1. Introduction 
 
The gold standard for establishing the clinical effectiveness and safety of a pharmaceutical 
technology is to conduct a randomised controlled trial (RCT). RCTs are the mainstay of 
research and development of new medicines, and are used to establish reliable comparative 
efficacy estimates.(1) The random allocation of patients between an intervention and control 
arm reduces confounding as compared to other types of study design where there is no 
randomisation.(2,3) This is reflected in the National Institute for Health and Care Excellence 
(NICE) guidance for technology appraisals which states that RCTs are “considered to be 
most appropriate for measures of relative treatment effect” and outlines that the “problems of 
confounding, lack of blinding, incomplete follow-up and lack of a clear denominator and 
endpoint occur more commonly in non-randomised studies and non-controlled trials than in 
RCTs”.(4) 
 
Clinical equipoise, defined as the absence of certainty about the superiority of alternative 
treatment options for a given indication, is a fundamental ethical criterion to randomly 
allocate participants to different treatment groups.(5) However, this criterion may not be 
necessary in the context of precision medicine with targeted therapies, where earlier studies 
have demonstrated a large magnitude of treatment effect. In such cases, some observers 
have postulated that RCTs may not be necessary.(6–8) Additionally, in the context of small 
populations, RCTs may be unethical and misleading, as results could be statistically 
underpowered.(9) As a result, drug licensing agencies such as the European Medicines 
Agency (EMA) may grant marketing authorisations to pharmaceutical technologies with no 
RCT data, when there is certainty that the product’s benefit outweighs potential harm (10).  
 
Once products are on the market, health technology assessment (HTA) agencies such as 
the National Institute for Health and Care Excellence (NICE) are responsible for evaluating 
not only the relative benefits but also the cost-effectiveness of novel technologies compared 
to existing alternatives in established use in clinical practice. Reliance on non-RCT data 
poses significant challenges for HTA agencies that are faced with increased uncertainty 
regarding the comparative clinical effectiveness, and therefore the cost-effectiveness 
estimates of pharmaceutical products.(11,12)  
 
In the absence of a controlled trial, alternative methods are required to generate relative 
clinical effectiveness estimates against comparator agents. Such estimates are an essential 
component for economic evaluation analyses conducted to establish the value of new 
agents. For example, an external control could be considered in an economic evaluation 
model using either historical data or a self-control.(13) According to technical guidance 
developed by NICE’s Decision Support Unit, use of a regression model is the preferred 
option to adjust for the effects of covariates when using an external control, although this is 
only possible when individual patient-level data are available for both the non-controlled trial 
and external control.(14)  
 
Our objective in this paper was to review NICE appraisals between 2000 and 2016 that 
calculated comparative clinical effectiveness estimates using non-RCT data.  We reviewed 
the methods used and compared the final published committee recommendation for these 
technologies versus those where comparative clinical effectiveness estimates were 
calculated using RCT data.  
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2. Methods 
 
2.1.  Identification of Pharmaceutical Technologies 
We adopted a two-pronged approach to identify pharmaceutical technologies whereby 
comparative clinical effectiveness estimates in NICE technology appraisals were calculated 
using non-RCT data. First, one researcher systematically reviewed all publicly available 
guidance documents from NICE single technology appraisal (STA), multiple technology 
appraisal (MTA) and highly specialised technology (HST) processes published between 
January 2010 and December 2016. Second, we reviewed all NICE STA, MTA, HST 
guidance published between January 2000 and December 2016 which appraised 
pharmaceutical technologies listed within two previously published systematic reviews  of 
pharmaceutical technologies which were granted EMA marketing authorisation without RCT 
data between 1999-2014.(10,15) 
 
For each technology appraisal, the corresponding clinical and economic evidence within 
NICE committee papers and evidence review group (ERG) reports were reviewed. NICE 
committee members are selected from the Institute itself, the National Health Service (NHS), 
patient and carer organisations, academia and the pharmaceutical industry.(16) The ERG 
reports are produced by a group of independent experts, in academia, and commissioned by 
the National Institute for Health Research (NIHR) to review and critique both the clinical and 
cost-effectiveness evidence available for each technology under appraisal.(4)  
 
As the NICE MTA process considers multiple pharmaceutical technologies for the same 
indication, each individual pharmaceutical technology under MTA with its own corresponding 
clinical and economic evidence base was reviewed separately.  
 
We excluded all non-pharmaceutical technology appraisals and those which were 
subsequently updated or terminated due to manufacturer non-submission. 
 
2.2.  Eligibility Criteria  
Pharmaceutical interventions reviewed by the NICE STA, MTA and HST appraisal 
processes were screened and categorised by one researcher as either a non-RCT or an 
RCT-based technology. A non-RCT based technology was defined as a pharmaceutical 
technology whereby the comparative clinical effectiveness estimates used within the 
economic evaluation model were calculated using non-RCT data. Non-RCT data could either 
be obtained from uncontrolled studies (i.e., a single-arm trial or a trial without a concurrent 
comparator group) or the intervention arm of an RCT interpreted as a single-arm trial by 
NICE. The latter occurred when the original comparator included in the RCT was deemed 
not to be relevant to the NICE decision scope (as specified in the published appraisal 
report). 
 
We relied on the ERG’s final economic evaluation model. The ERG may choose to alter the 
economic evaluation model submitted by the manufacturer to correct errors, consider 
different clinical or cost inputs, or modify the structure of the model. The ERG’s final 
economic evaluation model is therefore the most comprehensive reflection of available 
evidence which ultimately informs the NICE assessment.  
 
The final sample of technologies was checked and confirmed by a senior member of the 
research team.  
 
2.3. Data Extraction 
One researcher reviewed the appraisal guidance and ERG reports and collected data on (1) 
the methods for establishing comparative clinical effectiveness estimates, (2) NICE 
recommendations, and (3) NICE committee comments.   
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2.3.1. Methods to establish comparative clinical effectiveness estimates 
For each technology in our sample, within the final ERG’s economic evaluation, an 
unanchored indirect comparison was utilised to estimate comparative clinical effectiveness. 
The external control and methods used to estimate comparative clinical effectiveness in the 
economic model was identified. It was also determined if a meta-analysis or regression 
model was used in the final economic model to adjust for covariates. 
 
 
2.3.2. NICE Recommendations  
One researcher reviewed the NICE committee papers to characterise the corresponding 
recommendations for all technologies, including both the committee decision outcome and 
any use of patient access schemes. The committee decision outcome could be 
‘Recommended’ (approved with no restrictions), ‘Optimised’ (approved within a specified 
patient subgroup), ‘Not Recommended’ (not approved for routine use in the NHS), or ‘Only in 
Research’ (approved within a research setting). Many recommendations by NICE are based 
on a patient access scheme in which the cost-effectiveness of a technology under appraisal 
is improved by offering the technology at a discounted price. The NICE recommendations 
were reviewed for all technology appraisals published by NICE between January 2000 and 
December 2016.  
 
2.3.3. NICE Committee Comments 
For all technologies in our sample, one researcher reviewed the key conclusions of NICE 
committee documents to highlight any additional factors considered as well as concerns 
regarding the clinical evidence base and/or incremental cost-effectiveness ratio (ICER) 
estimates to gain an insight into the committee’s decision-making process.  
 
 
3. Results 
 
3.1. Identified Pharmaceutical Technologies 
We identified a total of 429 NICE technology appraisals between January 2000 and 
December 2016 (Figure 1). Of these, we excluded 120 as they either included non-
pharmaceutical technologies (37), were subsequently updated (57) or were terminated due 
to manufacturer non-submission (26). In the latter two cases, NICE committee papers were 
not publicly available. Reviewing the EMA initial marketing authorisation documents revealed 
4/26 (15%) of these terminated technologies were approved on the basis of a pivotal trial 
with non-RCT data. All 26 terminated technologies were due to manufacturer non-
submission.  
 
The remaining 309 technology appraisals included a total of 489 individual pharmaceutical 
products. Of these 489 pharmaceutical technologies, 22 (4%) individual pharmaceuticals 
across 20 technology appraisals were based on non-RCT data and therefore met our 
eligibility criteria. 12 (55%) had an oncology indication, 6 (27%) had a hepatology indication, 
3 (14%) had a rheumatology indication and 1 (5%) had an immunology indication.  
 
3.2. Methods used to establish Comparative Efficacy 
When choosing an external control to establish comparative clinical effectiveness estimates 
in the economic model, 13 (59%) used previously published trials, 6 (27%) used 
observational data, 2 (9%) used expert opinion and 1 (5%) used a responder vs non-
responder analysis. (Table 2). Only 5 (23%) appraisals utilised a regression model, and only 
6 (27%) appraisals used a meta-analysis to combine results from multiple studies. 
Comparative clinical effectiveness estimates for 14 pharmaceutical technologies (64%) were 
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calculated using a naive unadjusted indirect comparison against an external control, possibly 
due to a lack of individual patient level data. 
 
3.3. NICE Recommendations 
There was small differences between technologies in our sample (appraised on the basis of 
non-RCT data) vs technologies with RCT data receiving the NICE Committee decision 
outcome of ‘Recommended’ 10/22 vs 289/467 (45% vs 62%) or ‘Not Recommended’ 3/22 vs 
81/467 (14% vs 17%) (Table 1). Technologies in our sample were more than twice as likely 
to receive the NICE Committee decision outcome of ‘Optimised’ as compared to those with 
RCT data (9/22 vs 91/467; 41% vs 19%). The ‘Only In Research’ designation was not used 
for non-RCT-based pharmaceutical technologies and for 6/467 (1%) of RCT-based 
pharmaceutical technologies.  
 
Technologies with non-RCT data were more likely to utilise a patient access scheme as 
compared to those with RCT data; 7/22 vs 111/467 (32% vs 24%) (Table 1). All patient 
access schemes were financially-based except for one for a non-RCT-based technology.  
This scheme relied on a combination of a financial and performance-based patient access 
scheme, i.e. a managed access agreement.(17) 
 
 
3.4. NICE Committee Comments 
Several factors were considered by NICE Committees when evaluating technologies with 
non-RCT data. The most frequent factors were significant unmet need (11/22, 50%), a small 
patient population (6/22, 27%) and cases when early trials had shown substantial benefit 
(2/22, 9%). The small sample size limited the possibility to explore the association between 
NICE committee recommendations and these factors (Table 1) All committees explicitly 
highlighted concerns regarding the clinical evidence for all 22 technologies in our sample. 
These concerns included the immaturity of data, and the uncertainty associated with the lack 
of a direct comparator. Conversely, issues regarding the cost-effectiveness of each 
technology were more inconsistent, they were present for the 2 ‘Not Recommended’ 
technologies where an ICER estimate was available (100%, 2/2), the majority of the 9 
‘Optimised’ technologies (78%, 7/9) and rarely present for the 10 ‘Recommended’ 
technologies (20%, 210). (Table 1) Concerns were typically raised when the associated 
ICER estimate was above an acceptable threshold.    
 
4. Discussion 
 
4.1. Summary of Findings 
Our review of NICE appraisals conducted between 2000 and 2016 identified 22 
pharmaceutical technologies that relied on non-RCT data when generating comparative 
efficacy estimates used in the economic model. In these instances, we did not identify a 
consistent methodological approach to compare the technology to its comparators specified 
in the decision scope. Whilst existing guidelines recommend the use of statistical methods to 
adjust for covariates,(14,18) a regression model was used in only 5 out of 22 appraisals 
identified in our review. Final recommendations did not differ for technologies with and 
without RCT data.  
 
Previous research has indicated that the strongest predictor for a NICE recommendation is 
the ICER estimate.(19) Other factors which may influence NICE recommendations include 
severity of underlying illness, end-of- life considerations, disadvantaged populations, unmet 
need and paediatric indications.(20) Our findings are consistent with the previous literature. 
We found no notable differences between technologies appraised on the basis of non-RCT 
or RCT data receiving a positive (86% vs 83%) or negative (14% vs 17%) recommendation 
from NICE. We found that NICE Committees considered several additional factors when 
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appraising technologies on the basis of non-RCT data, including unmet clinical need, small 
patient populations, and large treatment effects. Amongst the positive recommendations 
there was a higher proportion of technologies with non-RCT data receiving the ‘Optimised’ 
decision outcome (41% vs 19%), likely reflecting the fragmented nature of the target patient 
population. In these circumstances, a patient population may be defined by a disease stage 
or other subgroup and be limited in numbers; conducting an RCT may therefore be 
challenging.  
 
Reviewing a recent EMA report, it was found that 6/22 (27%) of these technologies were 
granted conditional marketing authorisation by the EMA.(21)Despite several alternative 
strategies to mitigate the uncertainty associated with relative clinical effectiveness estimates 
derived from non-RCT data, they were seldom used by manufacturers or ERGs. Firstly, the 
‘Only In Research’ recommendation was not used for any non-RCT based technologies. 
Although whilst the ‘Only In Research’ designation may be appropriate in some cases, this 
must be balanced against delayed access to medicines for patients.(22) Secondly, patient 
access schemes offer another option to mitigate uncertainty regarding value of new 
technologies. Interestingly, there was only a small difference between technologies with and 
without RCT data utilising a patient access scheme. Furthermore, only one of these 
schemes was performance-based. This may reflect the methodological challenges 
associated with collecting real-world data following market entry.(23) 
 
4.2.  Implications  
To combat significant uncertainty associated with approving technologies based on non-RCT 
data alone, novel risk sharing approaches are needed. For example, NICE, NHS England, 
and the UK Department of Health have launched a new Cancer Drugs Fund (CDF), which 
fund oncology medications while further data are collected. For drugs recommended within 
the CDF, a managed access agreement (MAA) is agreed with both a data collection and a 
commercial agreement.(24). Similar initiatives to address clinical uncertainty are also being 
considered for non-oncology medications. Furthermore, the ADAPT SMART project has 
begun to explore how adaptive pathways and performance based managed access 
schemes could be utilised. (25)  
 
Although only a small number of pharmaceutical technologies were appraised on the basis 
of non-RCT data during our study period, the majority were in the last few years. Recent 
research has shown that larger effect sizes in noncontrolled studies are associated with 
higher rates of EMA licensing approval.7 Whilst this offers useful insight, clear criteria are 
needed to specify the circumstances in which noncontrolled trials are appropriate. Currently, 
the uncertainty in guidance represents a significant challenge for the pharmaceutical 
industry, regulatory authorities and HTA organisations. A collaborative technical advisory 
group involving both regulatory authorities such as the EMA and HTA organisations could 
begin efforts towards outlining guidance for a more consistent approach to both assessing 
the suitability of non-RCT data in evidence submissions and accruing further evidence over 
time. 
 
4.3. Limitations 
This study has a number of limitations. First, although our review comprehensively captures 
NICE appraisals of technologies that received EMA approvals without RCT data, we may 
have missed technologies from 2000 to 2009 if NICE considered the comparator arm of 
some trials to be irrelevant for the decision scope during this period. Second, while one 
researcher was involved in screening the appraisals extracting data from technology 
appraisals and associated documents, a senior member of the research team verified the 
sample. Third, our sample size was small, as technologies appraised on the basis of RCT 
data constitute the majority of NICE appraisals. However, half of the technologies without 
RCT data in our sample were appraised in the last 2 years.  
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5. Conclusion 
 
From 2000 to 2016, 22 technologies were appraised by NICE based on non-RCT data. The 
methods used to calculate comparative efficacy estimates in the absence of comparative 
trials varied. While regression methods can decrease the uncertainty associated with the 
evidence base of these technologies, this relies upon the availability of individual patient-
level data for any external control selected. Only a minority of the technologies appraised on 
the basis of non-RCT data received a negative recommendation.  
 
Authors’ Contributions: The conception and design of the study were completed by MA, HN, 
DM, LO and EM. Acquisition of data was done by MA and HN. Analysis of data was done by 
MA. Interpretation of data was handled by MA and HN. Drafting of manuscript was 
completed by MA and HN. Critical revisions were done by all authors. All authors gave final 
approval of the completed manuscript.   
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Table 1. Characteristics of technology appraisals with economic evaluations using non-RCT data to establish comparative clinical efficacy 
No Year NICE  
Programme 
Technology Indication  
Therapeutic 
Area 
PAS Additional Factors 
considered by NICE 
Committees 
NICE Committee 
Concerns 
Efficacy 
Estimate 
ICER 
Estimate 
NICE Recommendation: Not Recommended 
178 2009 MTA Sunitinib  Advanced and/or metastatic renal cell 
carcinoma (2nd line) 
Oncology Yes Significant Unmet Need Yes N/A 
202 2010 STA Ofatumumab Chronic lymphocytic leukaemia refractory 
to fludarabine and alemtuzumab 
Oncology Yes Early trial showed 
substantial benefit 
Yes Yes 
209 2010 MTA Imatinib 
600mg/800mg 
Unresectable and/or metastatic 
gastrointestinal stromal tumours 
Oncology No Small Patient 
Population 
Yes Yes 
NICE Recommendation: Optimised 
195 2010 MTA Adalimumab Rheumatoid arthritis after the failure of a 
TNF inhibitor 
Rheumatology No Nil Yes Yes 
195 2010 MTA Etanercept Rheumatoid arthritis after the failure of a 
TNF inhibitor 
Rheumatology No Nil Yes Yes 
195 2010 MTA Infliximab Rheumatoid arthritis after the failure of a 
TNF inhibitor 
Rheumatology No Nil Yes Yes 
330 2015 STA Sofosbuvir Chronic hepatitis C Hepatology No Early trial showed 
substantial benefit 
Yes Yes 
363 2015 STA Ledipasvir-sofosbuvir Chronic hepatitis C Hepatology No Significant unmet need Yes Yes 
364 2015 STA Daclatasvir Chronic hepatitis C Hepatology No Significant unmet need Yes Yes 
HST1 2015 HST Eculizumab Atypical haemolytic uraemic syndrome Nephrology No Small patient 
population  
Significant Unmet Need 
Yes Yes 
408 2016 STA Pegaspargase Acute lymphoblastic leukaemia Oncology No Paediatrics: Nil 
Adults: Small 
Population 
Yes No 
410 2016 STA Tamlimogene 
Laherparepvec 
Unresectable metastatic melanoma Oncology Yes Small patient 
population.  
Significant unmet need 
Yes No 
NICE Recommendation: Recommended 
23 2001 MTA Temozolonmide Recurrent malignant glioma Oncology No Small patient 
population.  
Significant Unmet Need 
Yes Yes 
86 2004 MTA Imatinib Unresectable and/or metastatic gastro-
intestinal stromal tumours 
Oncology No Significant Unmet Need Yes No 
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PAS: Patient Access Scheme ERG: Evidence Review Group NICE: National Institute for Health and Care Excellence  ICER: Incremental Cost-Effectiveness Ratio STA: Single 
Technology Appraisal; MTA: Multiple Technology Appraisal; HST: Highly-Specialised Technologies. 
 
185 2010 STA Intravenous Trabectin advanced soft tissue sarcoma Oncology Yes Small patient 
population.  
Significant Unmet Need 
Yes No 
246 2012 STA Pharmalgen Bee and wasp venom allergy Immunology No Nil Yes No 
300 2013 MTA Peginterferon alfa Chronic hepatitis C in children and young 
people 
Hepatology No Nil Yes No 
331 2015 STA Simeprevir genotype 1 or 4 chronic hepatitis C Hepatology No Nil Yes No 
365 2015 STA Ombitasvir-
Paritaprevir-Ritonavir 
Chronic hepatitis C Hepatology No Nil Yes No 
395 2016 STA Certinib Non-small-cell, anaplastic lymphoma 
kinase positive, previously 
treated 
Oncology Yes Significant Unmet Need Yes No 
401 2016 STA Bosutinib Previously-treated chronic 
myeloid leukaemia 
Oncology Yes Significant Unmet Need Yes No 
416 2016 STA Osimertinib Metastatic EGFR and T790M mutation-
positive non-small-cell lung cancer 
Oncology Yes Significant Unmet Need Yes Yes 
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Table 2. Methods used for technology appraisals with economic evaluations using non-RCT data to establish comparative clinical efficacy 
No Year Name Intervention 
Efficacy Data 
Comparators 
Efficacy Data 
Comparison Method Meta-
Analysis 
Regression 
Model 
NICE Recommendation: Not Recommended 
178 2009 Sunitinib  Two Uncontrolled Studies No Comparison made No Comparison made No No 
202 2010 Ofatumumab Single uncontrolled study* 
(Responders) 
 
Single uncontrolled study* 
(Non-responders) 
Responder vs Non-Responder 
Analysis 
No Yes  
209 2010 Imatinib 
600mg/800mg 
Multiple uncontrolled studies Observational Study Naïve unadjusted Indirect 
comparison 
No No 
NICE Recommendation: Optimised 
195 2010 Adalimumab Single uncontrolled study Multiple uncontrolled trials and 
RCTs 
Naïve unadjusted Indirect 
comparison 
Yes 
(Comparators) 
No 
195 2010 Etanercept Single uncontrolled study Multiple uncontrolled trials and 
RCTs 
Naïve unadjusted Indirect 
comparison 
Yes 
(Comparators) 
No 
195 2010 Infliximab Single uncontrolled study Multiple uncontrolled trials and 
RCTs 
Naïve unadjusted Indirect 
comparison 
Yes 
(Comparators) 
No 
330 2015 Sofosbuvir Multiple uncontrolled studies Multiple uncontrolled studies 
and RCTs 
Naïve unadjusted Indirect 
comparison 
No No 
363 2015 Ledipasvir-
Sofosbuvir 
Multiple uncontrolled studies Multiple uncontrolled studies 
and RCTs 
Naïve unadjusted Indirect 
comparison 
No No 
364 2015 Daclatasvir Multiple uncontrolled studies Multiple uncontrolled studies 
and RCTs 
Naïve unadjusted Indirect 
comparison 
No No 
HS
T1 
2015 Eculizumab Single uncontrolled study Observational dataset Naïve unadjusted Indirect 
comparison 
No No 
408 2016 Pegaspargase Paediatric: One uncontrolled 
study 
Adult: Multiple uncontrolled 
studies 
Paediatric: Multiple single-
arms of RCTs  
Adult: Expert Opinion 
Paediatrics: Naïve unadjusted 
Indirect comparison 
Adult: Expert Opinion  
≤25 years- 
Yes 
(Comparators) 
>25 years-No 
No 
410 2016 Tamlimogene 
Laherparepvec 
Single-arm of an RCT Multiple RCTs  Adjusted Indirect Comparison No Yes  
NICE Recommendation: Recommended 
23 2001 Temozolomide Single-arm of an RCT Multiple uncontrolled studies Naïve unadjusted indirect 
comparison 
Yes 
(Comparators) 
No 
86 2004 Imatinib Single uncontrolled study Observational Study Naïve unadjusted Indirect 
comparison 
No No 
185 2010 Intravenous 
Trabectin 
Single uncontrolled study Observational dataset Adjusted Indirect Comparison No Yes 
246 2012 Pharmalgen Multiple uncontrolled studies Observational Study Naïve unadjusted Indirect 
comparison 
Yes 
(Intervention) 
No 
300 2013 Peginterferon alfa Single uncontrolled study Expert Opinion Expert Opinion No No 
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*This was the same study    
NICE: National Institute for Health and Care Excellence   RCT: Randomised Controlled Trial 
331 2015 Simeprevir 
(Genotype 4) 
Single uncontrolled study Single-arms of an RCT Adjusted Indirect comparison No No 
365 2015 Ombitasvir-
Paritaprevir-
Ritonavir 
Multiple uncontrolled studies Multiple uncontrolled studies 
and RCTs 
Adjusted Indirect Comparison Yes Yes  
395 2016 Certinib Multiple uncontrolled studies Single uncontrolled study Naïve unadjusted Indirect 
comparison 
No No 
401 2016 Bosutinib Single uncontrolled study Observational Study Naïve unadjusted Indirect 
comparison 
No No 
416 2016 Osimertinib Multiple uncontrolled studies One RCT Adjusted indirect comparison Yes Yes 
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Table 3. NICE Committee Recommendations 
 
Non-RCT based 
Technologies 
RCT based 
Technologies 
Decision Outcome 
Recommended 10/22 (45%) 289/467 (62%) 
Not Recommended 3/22 (14%)  81/467 (17%) 
Optimised 9/22 (41%) 91/467 (19%) 
Only in Research 0/22 (0%) 6/467 (1%) 
Patient Access Scheme 
Patient Access 
Scheme 7/22 (32%) 111/467 (24%) 
RCT: randomised controlled trial.  
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Figure 1. Flow Diagram of Study Selection Process for Appraisals in the Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
NICE: National Institute for Health and Care Excellence; STA: single-technology appraisals; 
MTA: multiple-technology appraisals; HST: highly-specialised technologies;  
 
 
Between 2000-2016 NICE published 429 
Technology Appraisals 
• STA: 276 
• MTA: 150 
• HST: 3 
A review of clinical and cost-
effectiveness sections within 
Evidence Review Group and 
NICE Committee Papers of 
all technology appraisals 
2010-16 
Results 
• 22 (4.5%) Pharmaceutical Technologies in which comparative 
clinical effectiveness is established with uncontrolled data 
• 467 (95.5%) Pharmaceutical Technologies in which 
comparative clinical effectiveness is established with RCT data 
Excluded 120: 
• 37 Devices/Non-
Pharmaceutical 
• 57 Updated/Replaced 
• 26 Terminated-Non 
Submission 
 
Remaining 309 Technology Appraisals 
Covering a total of: 
• 489 Individual 
Pharmaceutical Technologies 
A review of clinical and cost-effectiveness sections within 
Evidence Review Group and NICE Committee Papers of 
all technology appraisals for pharmaceutical 
technologies contained within:  
Hatswell et al (2016) Regulatory approval of pharmaceuticals 
without a randomised controlled study: analysis of EMA and 
FDA approvals 1999–2014. BMJ Open, 6:e01166 
Hatswell et al (2017) Economic Evaluations of Pharmaceuticals 
Granted a Marketing Authorisation Without the Results of 
Randomised Trials: A Systematic Review and Taxonomy. 
Pharmacoeconomics, 35:163-176 
